Cardiovascular Systems, Inc. (CSII)
| Market Cap | 1.62B |
| Revenue (ttm) | 230.53M |
| Net Income (ttm) | -23.30M |
| Shares Out | 38.91M |
| EPS (ttm) | -0.62 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 29 |
| Last Price | $40.83 |
| Previous Close | $40.94 |
| Change ($) | -0.11 |
| Change (%) | -0.27% |
| Day's Open | 40.98 |
| Day's Range | 40.53 - 41.37 |
| Day's Volume | 199,414 |
| 52-Week Range | 29.59 - 48.28 |
ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients wit...
ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS, INC. TO WEBCAST FISCAL 2021 FOURTH-QUARTER EARNINGS CONFERENCE CALL WEDNESDAY, AUGUST 4
Cardiovascular Systems, Inc. to Participate at the Raymond James Human Health Innovations Conference
ST. PAUL, Minn.--(BUSINESS WIRE)--CSII at Raymond James Conf.
ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS, INC. ANNOUNCES U.S. COMMERCIAL LAUNCH OF JADE OVER-THE-WIRE NON-COMPLIANT PERIPHERAL BALLOON CATHETERS
Cardiovascular Systems (CSII) is progressing well with its objective to introduce OAS globally.
Cardiovascular Systems' (CSII) Diamondback 360 Coronary OAS helps in restoring native vessel compliance, simplify procedural workflow and enhance percutaneous coronary intervention outcomes.
ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients wit...
Increase in vaccinations and simultaneous decrease in COVID-19 hospitalizations in February and March result in improved procedure volumes for Cardiovascular Systems (CSII) in Q3.
Cardiovascular Systems (CSII) delivered earnings and revenue surprises of -50.00% and -0.25%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
ST. PAUL, Minn.--(BUSINESS WIRE)--CSI Q3 Earnings Release
ST. PAUL, Minn.--(BUSINESS WIRE)--JOURNAL OF MEDICAL ECONOMICS ARTICLE DEMONSTRATES ECONOMIC BENEFITS OF CARDIOVASCULAR SYSTEMS ORBITAL ATHERECTOMY
ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients wit...
ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII) will host a live webcast of its fiscal 2021 third-quarter conference call on Thursday, May 6, 2021, at 3:30 p.m. CT (...
Cardiovascular Systems' (CSII) investment in CarePICS will advance patient access to the suitable treatment at the right time, thereby leading to improved care and reduced amputations.
ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS, INC. ANNOUNCES INVESTMENT AND ACQUISITION OPTION AGREEMENT WITH TELEHEALTH COMPANY, CAREPICS, LLC
ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS, INC. TO PARTICIPATE AT THE 20TH ANNUAL NEEDHAM HEALTHCARE CONFERENCE
Cardiovascular Systems' (CSII) acquisition of Peripheral Support Catheters will enhance outcomes for patients undergoing complex peripheral and coronary interventions.
ST. PAUL, Minn.--(BUSINESS WIRE)--ViperCross
Cardiovascular Systems' (CSII) WIRION demonstrated a major adverse event rate of 1.9%, which is lower than the earlier reported rates for other lower extremity embolic protection filters.
ST. PAUL, Minn.--(BUSINESS WIRE)--WIRION
Cardiovascular Systems (CSII) reported earnings 30 days ago. What's next for the stock?
ST. PAUL, Minn.--(BUSINESS WIRE)--CSII Q3 Conferences
Cardiovascular System's (CSII) Diamondback 360 Coronary OAS provides physicians in Europe with an effective treatment option for difficult-to-treat patient population.
ST. PAUL, Minn.--(BUSINESS WIRE)--First patient treated in Europe
Cardiovascular Systems (CSII) registers dismal revenues despite gradual recovery in business amid the pandemic.
Cardiovascular Systems (CSII) delivered earnings and revenue surprises of 100.00% and -1.69%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Cardiovascular Systems (NASDAQ:CSII) were unchanged in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 100.00% year over year to ($0....
ST. PAUL, Minn.--(BUSINESS WIRE)--CSI Q2 Financial Results
ST. PAUL, Minn.--(BUSINESS WIRE)--CSI Q2 Financial Results
ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS, INC. ANNOUNCES PARTNERSHIP WITH CHANSU VASCULAR TECHOLOGIES, LLC TO DEVELOP NEW DRUG-COATED BALLOON TECHNOLOGY
ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS, INC. ANNOUNCES SACHIN H. JAIN, MD, MBA, JOINS BOARD OF DIRECTORS
Cardiovascular Systems (CSII) aims to expand treatment options in Europe for patients suffering from severely calcified coronary artery disease following the receipt of regulatory clearance.
ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS, INC. RECEIVES CE MARK FOR DIAMONDBACK 360® CORONARY ORBITAL ATHERECTOMY SYSTEM
ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS, INC. TO WEBCAST FISCAL 2021 SECOND-QUARTER EARNINGS CONFERENCE CALL WEDNESDAY, FEBRUARY 3
ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS, INC. TO PRESENT AT THE 23RD ANNUAL NEEDHAM VIRTUAL GROWTH CONFERENCE
Cardiovascular Systems (CSII) reported earnings 30 days ago. What's next for the stock?
ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS, INC. TO PRESENT AT THE STIFEL 2020 VIRTUAL HEALTHCARE CONFERENCE
Cardiovascular Systems (CSII) registers dismal segmental revenues despite gradual recovery in business amid the pandemic.
Cardiovascular Systems, Inc. (CSII) CEO Scott Ward on Q1 2021 Results - Earnings Call Transcript
Cardiovascular Systems (CSII) delivered earnings and revenue surprises of 78.26% and 7.59%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS, INC. REPORTS FISCAL 2021 FIRST-QUARTER FINANCIAL RESULTS
Cardiovascular Systems (CSII) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII) will host a live webcast of its fiscal 2021 first-quarter conference call on Wednesday, November 4, 2020, at 3:30 p.m...
ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients wit...
ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients wit...
Cardiovascular Systems' (CSII) encouraging REACH PVI study outcome and launch of a physician finder are positives.
Cardiovascular Systems (CSII) reported earnings 30 days ago. What's next for the stock?
ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS, INC.
Cardiovascular Systems (CSII) registers significant decline in STEMI activations in Q4 earnings as patients avoid hospitals.
About CSII
Cardiovascular Systems, Inc., a medical device company, develops and commercializes various devices to treat peripheral and coronary artery diseases in the United States. The company offers peripheral artery disease products, which are catheter-based platforms to treat a range of plaque types in above and below the knee leg arteries, including calcified plaque, as well as address various limitations related with surgical, catheter, and pharmacological treatment alternatives; and peripheral support products. It also provides Diamondback 360 Coro... [Read more...]
| Industry Medical Devices | IPO Date Feb 26, 2009 |
| CEO Scott Ward | Employees 779 |
| Stock Exchange NASDAQ | Ticker Symbol CSII |
Financial Performance
In 2020, CSII's revenue was $236.55 million, a decrease of -4.63% compared to the previous year's $248.02 million. Losses were -$27.24 million, 10,580.8% more than in 2019.
Analyst Forecasts
According to 10 analysts, the average rating for CSII stock is "Buy." The 12-month stock price forecast is 45.44, which is an increase of 11.29% from the latest price.